WLWenhua Lei

Wenhua Lei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenhua Lei has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Featured Cover

    by Yaoyu Zhang, Jialiang Zhang, Yanjiani Xu, Wenhua Lei, Fei Xu, Junli Li, Zisong Wei, Bo Su, Shuang Liu, Jing Zhou, et al.

  • Open Access

    The Senokine Gas6 Promotes Aortic Valve Calcification Through CaMKII–DRP1–Mediated Terminal Scission of Mitochondrial‐Derived Vesicles

    by Yaoyu Zhang, Jialiang Zhang, Yanjiani Xu, Wenhua Lei, Fei Xu, Junli Li, Zisong Wei, Bo Su, Shuang Liu, Jing Zhou, et al.

    Calcific aortic valve disease (CAVD) is an age‐associated valvular disorder in which calcification expands from discrete foci into adjacent tissue. We investigated whether mitochondrial‐derived vesicles (MDVs) released by human valvular interstitial cells (hVICs) exert pro‐calcific effects on recipient cells and how MDV release is regulated. Using ex vivo hemodynamic perfusion of human CAVD tissue, multi‐omics profiling, live‐cell single‐organelle tracking, MDV transfer assays, and in vivo Gas6 deletion, we found that calcifying hVICs hypersecreted MDVs that exerted pro‐calcific effects in recipient hVICs. High‐resolution imaging showed that mitochondria remodeled into donut‐shaped structures under pro‐osteogenic conditions; these structures served as physical platforms for MDV budding. Human CAVD valve tissues and hVICs treated with pro‐osteogenic medium also exhibited senescence‐associated features. Multi‐omics profiling identified growth arrest‐specific 6 (Gas6), a senokine, among 36 concordantly upregulated candidates. Functional analyzes showed that Gas6 promoted terminal MDV scission while leaving donut‐shaped mitochondrial precursor formation intact. Mechanistically, Gas6 promoted intracellular Ca 2+ accumulation, calcium/calmodulin‐dependent protein kinase II (CaMKII) activation, and dynamin‐related protein 1 (DRP1) phosphorylation at Ser616, supporting a Ca 2+ –CaMKII–DRP1 axis that facilitates terminal MDV scission. Pharmacological inhibition of CaMKII or DRP1 reduced MDV hypersecretion and subsequent recipient‐cell calcification, and Gas6 deletion in vivo attenuated valvular stenosis, calcification, and fibrotic remodeling. These findings identify Gas6‐dependent terminal MDV scission as a mechanism contributing to the intercellular propagation of valvular calcification in a CAVD context characterized by senescence‐associated features.

  • Long-Term Outcomes of BAV-0 Patients Compared With BAV-1 and TAV Patients After TAVR

    by Weiya Li, Yuheng Jia, Hongde Li, Yusuke Kobari, Junli Li, Yuan Feng, Yong Peng, Jiafu Wei, Zhengang Zhao, Tianyuan Xiong, et al.


  • Uric acid promotes aortic valve calcification via mediating valve interstitial cell osteogenic differentiation and endothelial dysfunction

    by Jialiang Zhang, Wenhua Lei, Jing Zhou, Yaoyu Zhang, Fangyang Huang, Mao Chen

    Aortic valve calcification is a lethal valvular heart disease lacking effective drug therapy. However, whether uric acid is involved in the development of aortic valve calcification is unclear. Two‐sample Mendelian randomization (MR) analyses confirmed the causal relationship between uric acid and valvular heart disease. Uric acid levels were assessed in aortic valve tissue from patients with/without aortic valve calcification. To investigate the impact of hyperuricemia on aortic valve calcification, apolipoprotein E knockout (ApoE −/− ) mice fed a high‐fat diet (HFD) were also given an adenine diet, with some receiving allopurinol in their drinking water. RNA sequencing was performed on valve interstitial cells (VICs) and endothelial cells (VECs) with/without uric acid. MR analysis has revealed a causal effect of uric acid levels on valvular heart disease. Furthermore, our clinical data indicate a positive correlation between elevated serum uric acid levels and aortic valve calcium score. Specifically, uric acid levels were upregulated in calcified valves. In ApoE −/− mice, an adenine‐diet‐induced hyperuricemia accelerated aortic valve calcification. RNA sequencing analysis demonstrated that uric acid‐promoted osteogenic differentiation, primarily through the activation of hypoxia‐inducible factor‐1alpha (HIF‐α). Additionally, uric acid impaired endothelial barrier function by activating HIF‐α, resulting in increased macrophage infiltration in ApoE −/− mice. Inhibiting HIF‐1α suppressed osteogenic differentiation and reduced endothelial injury both in vitro and in vivo in the presence of uric acid. This study reveals a new role of hyperuricemia in aortic valve calcification, suggesting uric acid‐lowering drugs or HIF‐1α inhibition as potential treatments for associated aortic valve calcification.


  • Association of serum levels of calcium, phosphate, and vitamin D with risk of developing aortic stenosis: the UK Biobank cohort

    by Congying Xia, Wenhua Lei, Yao Hu, Huazhen Yang, Xiaoxi Zeng, Mao Chen

    Aims: This study was aimed to investigate the associations of serum calcium, phosphate, and vitamin D levels with the risk of developing aortic stenosis (AS). Methods and results: We included 296 415 participants who were free of prior diagnosis of any valvular heart disease from the UK Biobank. Serum levels of phosphate, calcium, and vitamin D were measured. Incidental AS was determined by the records of hospital data. Cox regression was used to examine the association of serum mineral levels with incidental AS after adjustment for potential confounders. The mean age was 56.4 years (SD 8.14) and 53.3% of participants were women. During an average follow-up of 8.1 years, 1232 individuals developed AS. After adjustment, each 0.5-unit increase in serum phosphate level was associated with a 50% increase of AS risk (hazard ratio 1.50, 95% confidence interval 1.26–1.80). We observed no association of serum calcium and vitamin D levels with AS. Conclusion: Increased serum phosphate level, but not calcium or vitamin D, was associated with a higher risk of incident AS, this association did not differed substantially between patients with and without decreased kidney function. This finding implied that phosphate may be a potential interventional target for AS.


  • Open Access

    Sodium Lactate Accelerates M2 Macrophage Polarization and Improves Cardiac Function after Myocardial Infarction in Mice

    by Jialiang Zhang, Fangyang Huang, Li Chen, Guoyong Li, Wenhua Lei, Jiahao Zhao, Yanbiao Liao, Yijian Li, Changming Li, Mao Chen

    Background. After myocardial infarction, anti-inflammatory macrophages perform key homeostatic functions that facilitate cardiac recovery and remodeling. Several studies have shown that lactate may serve as a modifier that influences phenotype of macrophage. However, the therapeutic role of sodium lactate in myocardial infarction (MI) is unclear. Methods. MI was established by permanent ligation of the left anterior descending coronary artery followed by injection of saline or sodium lactate. Cardiac function was assessed by echocardiography. The cardiac fibrosis area was assessed by Masson trichrome staining. Macrophage phenotype was detected via qPCR, flow cytometry, and immunofluorescence. Signaling proteins were measured by Western blotting. Results. Sodium lactate treatment following MI improved cardiac performance, enhanced anti-inflammatory macrophage proportion, reduced cardiac myocytes apoptosis, and increased neovascularization. Flow-cytometric analysis results reported that sodium lactate repressed the number of the IL-6+, IL-12+, and TNF-α+ macrophages among LPS-stimulated bone marrow-derived macrophages (BMDMs) and increased the mRNA levels of Arg-1, YM1, TGF-β, and IL-10. Mechanistic studies revealed that sodium lactate enhanced the expression of P-STAT3. Furthermore, a STAT3 inhibitor eliminated sodium lactate-mediated promotion macrophage polarization. Conclusion. Sodium lactate facilitates anti-inflammatory M2 macrophage polarization and protects against MI by regulating P-STAT3.


  • Open Access

    MARCH5 restores endothelial cell function against ischaemic/hypoxia injury via Akt/eNOS pathway

    by Wenhua Lei, Junli Li, Changming Li, Li Chen, Fangyang Huang, Dan Xiao, Jialiang Zhang, Jiahao Zhao, Guoyong Li, Tianyi Qu, et al.

    MARCH5 is a critical regulator of mitochondrial dynamics, apoptosis and mitophagy. However, its role in cardiovascular system remains poorly understood. This study aimed to investigate the role of MARCH5 in endothelial cell (ECs) injury and the involvement of the Akt/eNOS signalling pathway in this process. Rat models of myocardial infarction (MI) and human cardiac microvascular endothelial cells (HCMECs) exposed to hypoxia (1% O2) were used in this study. MARCH5 expression was significantly reduced in ECs of MI hearts and ECs exposed to hypoxia. Hypoxia inhibited the proliferation, migration and tube formation of ECs, and these effects were aggravated by knockdown of MARCH5 but antagonized by overexpressed MARCH5. Overexpression of MARCH5 increased nitric oxide (NO) content, p‐eNOS and p‐Akt, while MARCH5 knockdown exerted the opposite effects. The protective effects mediated by MARCH5 overexpression on ECs could be inhibited by eNOS inhibitor L‐NAME and Akt inhibitor LY294002. In conclusion, these results indicated that MARCH5 acts as a protective factor in ischaemia/hypoxia‐induced ECs injury partially through Akt/eNOS pathway.


  • Open Access

    Transcatheter Aortic Valve Replacement in Patients with Aortic Stenosis Having Coronary Cusp Fusion versus Mixed Cusp Fusion Nonraphe Bicuspid Aortic Valve

    by Wen-Hua Lei, Yan-Biao Liao, Zi-Jie Wang, Yuan-Weixiang Ou, Jiay-Yu Tsauo, Yi-Jian Li, Tian-Yuan Xiong, Zhen-Gang Zhao, Xin Wei, Wei Meng, et al.

    Objectives. We aimed to assess the procedural and clinical results of transcatheter aortic valve replacement (TAVR) for nonraphe bicuspid aortic stenosis (AS) with coronary vs mixed cusp fusion. Background. It remains unclear whether cusp fusion morphology affects TAVR outcomes in patients with nonraphe bicuspid AS. Methods. This retrospective study enrolled consecutive patients with severe symptomatic AS and type-0 bicuspid aortic valve, who underwent TAVR at our institution between 2012 and 2017. TAVR outcomes were defined based on the Valve Academic Research Consortium-2 recommendations. Results. Compared to patients with mixed cusp fusion (44/71), those with coronary cusp fusion (27/71) had a larger ellipticity index for the aortic annulus (21.9% ± 9.0% vs 15.6% ± 9.3%, p=0.007) and increased left ventricular outflow tract obstruction (31.1% ± 9.4% vs 26.9% ± 7.5%, p=0.04) but comparable rates of second valve implantation (15.9% vs 14.8%), mild paravalvular leakage (PVL, 38.5% vs 30.2%), permanent pacemaker implantation (PPM, 25.9% vs 15.9%), and 30-day mortality (7.4% vs 6.8%). Use of a first-generation transcatheter heart valve was associated with higher risk for mild PVL (odds ratio (OR) = 4.37; 95% confidence interval (95% CI) = 1.14–16.75; p=0.03) but not PPM (OR = 0.77; 95% CI = 0.22–2.62; p=0.67), whereas a larger oversizing ratio tended to be associated with a higher PPM rate (OR = 1.49; 95% CI = 0.46–4.86; p=0.51) but lower incidence of mild PVL (OR = 0.51; 95% CI = 0.19–1.35; p=0.17). Conclusions. In AS patients with type-0 bicuspid valves, cusp fusion morphology does not affect the procedural or clinical results of TAVR. Use of second-generation transcatheter heart valves may provide more favorable results in such patients. This trial is registered with NCT01683474.